Homestead Advisers Corp Aerie Pharmaceuticals Inc Transaction History

Homestead Advisers Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 07, 2022	SELL	$7.02 - $13.33 $1.09 Million - $2.08 Million	-155,838 Closed	0 $0
Q3 2021 Nov 05, 2021	BUY	$11.32 - $16.63 $47,544 - $69,846	4,200 Added 2.77%	155,838 $1.78 Million
Q1 2021 May 07, 2021	BUY	$13.12 - $20.9 $419,840 - $668,800	32,000 Added 26.75%	151,638 $2.71 Million
Q4 2020 Feb 10, 2021	SELL	$9.12 - $14.49 $21,887 - $34,776	-2,400 Reduced 1.97%	119,638 $1.62 Million
Q3 2020 Nov 13, 2020	BUY	$10.46 - $14.46 $758,350 - $1.05 Million	72,500 Added 146.35%	122,038 $1.44 Million
Q2 2020 Aug 13, 2020	SELL	$12.0 - $16.13 $7,200 - $9,678	-600 Reduced 1.2%	49,538 $731,000
Q1 2020 May 14, 2020	SELL	$11.84 - $25.52 $13,852 - $29,858	-1,170 Reduced 2.28%	50,138 $677,000
Q4 2019 Feb 13, 2020	BUY	$17.72 - $25.1 $909,177 - $1.29 Million	51,308 New	51,308 $1.24 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Homestead Advisers Corp, based on Form 13F filings with the SEC.

Stay updated on Homestead Advisers Corp with notifications on news.